NCT07552285 The Enhancement of Diagnostic and Grading Efficacy of Prostate Cancer by New MRI Sequences: A Prospective Observational Study Based on New MRI Sequences in a Single Center
| NCT ID | NCT07552285 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Affiliated Hospital of Soochow University |
| Condition | Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2025-05-01 |
| Primary Completion | 2027-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2025-05-01 with a primary completion date of 2027-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial aims to explore the diagnostic efficacy and grading of prostate cancer by a novel MRI sequences such as MAGiC，OGSE,CEST,IVIM,etc.The main question it aims to answer is: Can the novel non-contrast multiparametric MRI imaging improve the accuracy of diagnosis and grading of prostate cancer? For patients with clinical suspicion of prostate cancer, both conventional and new sequences magnetic resonance scans are conducted, with surgical or biopsy pathological results serving as the gold standard.
Eligibility Criteria
Inclusion Criteria: 1. Patients with a high clinical suspicion of prostate cancer and elevated tPSA levels; 2. Patients with no prior history of other tumors; 3. Patients with no contraindications to MRI, including claustrophobia, presence of pacemakers, cardiac stents, or metal implants such as screws and plates. Exclusion Criteria: 1. The patient has a history of malignant tumors and has received corresponding treatment; 2. Prior to the MRI examination, the patient has undergone treatment for prostate cancer, including endocrine therapy, radiotherapy, etc.; 3. Patients who have previously undergone radical prostatectomy for prostate cancer.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07552285 clinical trial?
This trial is open to male participants only, aged 20 Years or older, up to 90 Years, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07552285 currently recruiting?
Yes, NCT07552285 is actively recruiting participants. Contact the research team at zhangqian0194@163.com for enrollment information.
Where is the NCT07552285 trial being conducted?
This trial is being conducted at Suzhou, China.
Who is sponsoring the NCT07552285 clinical trial?
NCT07552285 is sponsored by The First Affiliated Hospital of Soochow University. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.